He is examining the ability of surgically placed biologic scaffolds composed of ECM to augment the endogenous tissue injury response. Brian is especially interested in the ability of degradation products of ECM to promote immune modulation and how a modulated immune response affects the tissue remodeling process, including progenitor cell activity. Brian received his PhD from the University of Pittsburgh’s School of Medicine in 2013.